News Patients call for end to two-year row over CF drug funding UK patients are stepping up efforts to resolve the “heartbreaking” row that is denying their families access to Vertex’s groundbreaking cystic fibrosis (CF) drug Orkambi, after Sweden becam
News J&J's Tremfya gets funding in Germany and UK Johnson & Johnson’s psoriasis drug Tremfya has been given the green light for funding by cost-effectiveness bodies in the UK and Germany.
News Scotland's NHS to fund Ipsen cancer diarrhoea drug Decision welcomed as step forward for patients
News Pfizer will have to cut price of AML drug Mylotarg after NIC... NICE blocks access to 65% of patients on cost grounds
News Novartis/Amgen's migraine drug hits market at lower than exp... The FDA has approved the first in a new class of migraine drugs, Novartis and Amgen’s Aimovig, and at a lower than expected list price of $6,900.
Partner Content Partner Content Neil Levinson joins ACCRETIO as Strategy Director Neil Levinson joins ACCRETIO as Strategy Director
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.